c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty

Structure

Volumn 15, Issue 3, 2007, Pages 299-311

  Seeliger, Markus A ^a   Nagar, Bhushan ^a   Frank, Filipp ^a   Cao, Xiaoxian ^a   Henderson, M Nidanie ^a   Kuriyan, John ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

CELLCYCLE; SIGNALING

Indexed keywords

ABELSON KINASE; CYCLIN DEPENDENT KINASE; IMATINIB; PLATELET DERIVED GROWTH FACTOR; STEM CELL FACTOR;

ARTICLE; BINDING AFFINITY; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ENERGY BALANCE; GENE INACTIVATION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; THERMODYNAMICS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CHICKENS; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THERMODYNAMICS;

EID: 33847659183     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2007.01.015     Document Type: Article

References (42)

1. Atwell S., Adams J.M., Badger J., Buchanan M.D., Feil I.K., Froning K.J., Gao X., Hendle J., Keegan K., Leon B.C., et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279 (2004) 55827-55832
2. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843
3. Barker S.C., Kassel D.B., Weigl D., Huang X., Luther M.A., and Knight W.B. Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 34 (1995) 14843-14851
4. Bliska J.B., Guan K.L., Dixon J.E., and Falkow S. Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc. Natl. Acad. Sci. USA 88 (1991) 1187-1191
5. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
6. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., and Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295 (2000) 139-145
7. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1 (2002) 493-502
8. Cheng Y., and Prusoff W.H. Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
9. Cowan-Jacob S.W., Fendrich G., Manley P.W., Jahnke W., Fabbro D., Liebetanz J., and Meyer T. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13 (2005) 861-871
10. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., and Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature 363 (1993) 595-602
11. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
12. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
13. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
14. Fersht A.R. Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding (1999), W.H. Freeman, New York
15. Gonfloni S., Weijland A., Kretzschmar J., and Superti-Furga G. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat. Struct. Biol. 7 (2000) 281-286
16. Hantschel O., and Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5 (2004) 33-44
17. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron-density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
18. Knighton D.R., Zheng J.H., Ten Eyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., and Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253 (1991) 407-414
19. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 (2005) 172-187
20. LaFevre-Bernt M., Sicheri F., Pico A., Porter M., Kuriyan J., and Miller W.T. Intramolecular regulatory interactions in the Src family kinase Hck probed by mutagenesis of a conserved tryptophan residue. J. Biol. Chem. 273 (1998) 32129-32134
21. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., Cole P.A., and Kuriyan J. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4 (2006) e144
22. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61 (2005) 458-464
23. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., and Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279 (2004) 31655-31663
24. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., and Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
25. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., and Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112 (2003) 859-871
26. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallogr. A 276 (1997) 307-326
27. Sawyers C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1 (2002) 13-15
28. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., and Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3 (1999) 639-648
29. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
30. Seeliger M.A., Young M., Henderson M.N., Pellicena P., King D.S., Falick A.M., and Kuriyan J. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 14 (2005) 3135-3139
31. Seggewiss R., Lore K., Greiner E., Magnusson M.K., Price D.A., Douek D.C., Dunbar C.E., and Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105 (2005) 2473-2479
32. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
33. Sicheri F., Moarefi I., and Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385 (1997) 602-609
34. Songyang Z., Carraway III K.L., Eck M.J., Harrison S.C., Feldman R.A., Mohammadi M., Schlessinger J., Hubbard S.R., Smith D.P., Eng C., et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373 (1995) 536-539
35. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13 (1997) 513-609
36. Williams J.C., Weijland A., Gonfloni S., Thompson A., Courtneidge S.A., Superti-Furga G., and Wierenga R.K. The 2.35 Å crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J. Mol. Biol. 274 (1997) 757-775
37. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (2004) 6652-6659
38. Xu W., Harrison S.C., and Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385 (1997) 595-602
39. Xu W., Doshi A., Lei M., Eck M.J., and Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3 (1999) 629-638
40. Yamaguchi H., and Hendrickson W.A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384 (1996) 484-489
41. Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V., Biggs III W.H., Treiber D.K., Patel H.K., Zarrinkar P.P., Lockhart D.J., et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 66 (2006) 1007-1014
42. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149